Phase 2 × NIH × fludarabine phosphate × Clear all
NCT01168219 2022-08-04

Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 2 Completed
68 enrolled 11 charts
NCT00381550 2015-01-06

3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia

National Cancer Institute (NCI)

Phase 2 Completed
35 enrolled 8 charts
NCT00084695 2014-01-10

Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases

National Cancer Institute (NCI)

Phase 2 Unknown
25 enrolled
NCT00008307 2014-01-06

Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders

National Cancer Institute (NCI)

Phase 2 Unknown
52 enrolled
NCT00066417 2013-05-01

Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia

National Cancer Institute (NCI)

Phase 2 Terminated
51 enrolled
NCT00627666 2013-03-26

Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer

National Cancer Institute (NCI)

Phase 2 Completed
52 enrolled
NCT00806767 2011-05-17

Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer

National Cancer Institute (NCI)

Phase 2 Completed
82 enrolled
NCT00740467 2010-01-28

Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders

National Cancer Institute (NCI)

Phase 2 Unknown
50 enrolled